摘要
目的探讨吸入用布地奈德混悬液(商品名:普米克令舒)联合孟鲁司特治疗小儿慢性咳嗽的临床效果。方法130例慢性咳嗽患儿作为研究对象,运用随机数字表法将其分为对照组与试验组,各65例。对照组给予孟鲁司特治疗,试验组给予普米克令舒联合孟鲁司特药物治疗。比较两组患儿治疗前及治疗2周后的咳嗽严重度评分、咳嗽频度评分、第1秒用力呼气容积占预计值的百分比(FEV1%)、最大呼气流量(PEF)变化情况,临床治疗效果,咳嗽缓解时间、咳嗽消失时间。结果治疗前,两组咳嗽严重度评分、咳嗽频度评分、FEV1、PEF比较,差异无统计学意义(P>0.05);治疗2周后,试验组咳嗽严重度评分、咳嗽频度评分明显低于对照组,FEV1、PEF显著高于对照组,差异有统计学意义(P<0.05)。试验组临床治疗总有效率98.46%明显高于对照组的87.69%,差异有统计学意义(P<0.05)。试验组的咳嗽缓解时间(5.14±0.79)d、咳嗽消失时间(6.09±0.48)d明显短于对照组的(6.12±2.21)、(7.12±1.16)d,差异有统计学意义(P<0.05)。结论普米克令舒联合孟鲁司特治疗小儿慢性咳嗽临床效果显著,不仅能够有效改善咳嗽严重程度和咳嗽频度,提升FEV1%、PEF,还可有效缩短咳嗽缓解时间、咳嗽消失时间。
Objective To discuss the clinical effect of budesonide suspension for inhalation(trade name:Pulmicort)combined with montelukast in the treatment of chronic cough in children.Methods A total of 130 children with chronic cough as study subjects were divided into control group and experimental group by random numerical table,with 65 cases in each group.The control group was treated by montelukast,and the experimental group was treated by Pulmicort combined with montelukast.The cough severity score and cough frequency score before treatment and 2 weeks after treatment,percentage of forced expiratory volume in the first second to predicted value(FEV1%)and peak expiratory flow(PEF)changes,clinical treatment effect,cough relief time and disappearance time of cough were compared between the two groups.Results Before treatment,there was no statistically significant difference in cough severity score,cough frequency score,FEV1%and PEF between the two groups(P>0.05).2 weeks after treatment,cough severity score,cough frequency score of the experimental group was obviously lower than that of the control group,and FEV1%,PEF was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The total effective rate of clinical treatment 98.46%of the experimental group was obviously higher than that of the control group 87.69%,and the difference was statistically significant(P<0.05).The cough relief time(5.14±0.79)d and cough disappearance time(6.09±0.48)d of the experimental group was obviously shorter than that of the control group(6.12±2.21)and(7.12±1.16)d,and the difference was statistically significant(P<0.05).Conclusion Pulmicort combined with montelukast shows remarkable clinical effect in the treatment of chronic cough in children,which can not only reduce cough severity and frequency,improve FEV1%and PEF,but also shorten cough relief time and cough disappearance time.
作者
庾达荣
YU Da-rong(Department of Pediatrics,Maternal and Child Health Hospital of Huadu District,Guangzhou 510800,China)
出处
《中国现代药物应用》
2020年第15期7-9,共3页
Chinese Journal of Modern Drug Application
基金
2019年度广州市花都区医疗卫生一般科研专项项目立项(项目编号:花科工信字[2019]45号19-HDWS-072)项目名称:儿童呼吸道感染和感染后顽固性咳嗽相关性及其治疗的研究。
关键词
吸入用布地奈德混悬液
孟鲁司特
小儿慢性咳嗽
Budesonide suspension for inhalation
Montelukast
Chronic cough in children
